Researchers Coax Retinal Muller Glia Cells to Become Regenerating Neurons that Function

September 1, 2017: By Joan McKenna

1 Ophthalmic NewsResearchers have coaxed retinal Müller glia cells in an injured mouse eye to become regenerating neurons that become part of the eye’s circuitry, according to a study published July 26 in Nature.

The study, by Tom Reh, PhD, and his team at the UW Medicine in Seattle, was funded in part by the National Eye Institute.

Müller glia cells are retinal cells that support the health and functioning of neighboring neurons and also exhibit regenerative ability.

Earlier work by the team showed that activating a transcription factor called Ascl1 in newborn mice could direct Müller glia to become retinal neurons that activated genes involved in regeneration. However, in older mice, those genes became inaccessible.

Using the anti-cancer agent trichostatin A (TSA) made the genes accessible again, the scientists found.

For this study, the team used an adult mouse model genetically engineered to express Ascl1 in Müller glia in response to tamoxifen, a commonly used breast cancer drug.

They injected the mice with TSA and tamoxifen. Over the next several weeks, the shape and behavior of the cells showed evidence of regeneration.

About two weeks following injury, the cells responded to light as if they were interneurons, retinal cells that transmit signals from photoreceptors to the brain.

The cells also formed functioning synapses, or connections from one neuron to another, and had integrated with retinal cells that convey signals to the brain.

Reh said the approach could be useful for treatment of acute eye injuries and central retinal arterial occlusion. Reh’s lab is investigating other types of regenerative strategies to address all the retinal cell types.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Will Comply with FDA Warning Letter

GenSight Receives UK Approval to Start Phase I/II Trial of Gene Therapy for Retinitis Pigmentosa

US FDA Outlines Compounding Policy, Defines Drugs that are ‘Essentially Copies’

Major US Hospitals Plan to Create Generic Drug Company, NYT Reports

Glaukos’ iDose Travoprost Implant Achieves Sustained IOP Reduction in 12-Month Interim Cohort

RXi Plans to Out-License Ophthalmic Segment or Find Development Partner

Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

Iridex Sues Quantel Medical over Patent, Trademark Infringement

pSivida Submits NDA to US FDA for Durasert for Posterior Segment Uveitis

Alimera Sciences Refinances Debt with $40 Million Loan

LENSAR Acquires Mobile Laser Unit of Precision Eye Services

CES 2018 Features Dynafocals Smart Reading Glasses by PH Technical Labs

Novaliq Enrolls First Patient in Phase II Trial for Dry Eye Candidate, Establishes US Subsidiary

Allergan to Eliminate More than Thousand Jobs as Part of Restructuring

Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

Oculis Raises $20.3 Million in Series B Round

Pixium Vision Gets Green Light for US Study of PRIMA Retinal Implant in Atrophic Dry AMD

Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

Coming soon

2018 Ophthalmic Surgical Instruments Report: A Global Market Analysis for 2017 to 2023